A massive botulism outbreak tied to ByHeart baby formula has sickened over 50 infants across 19 states, with federal investigators now warning that every single product the company ever manufactured may have been contaminated since production began in 2022.
Story Overview
- 51 infants across 19 states contracted botulism from ByHeart formula since 2022
- FDA cannot rule out contamination in all ByHeart products ever produced
- Company had previous contamination issues and FDA warning letters
- Multiple lawsuits filed by families seeking accountability for negligence
Contamination Spans Entire Production History
The FDA expanded its investigation after discovering contamination appeared to persist across all production runs since ByHeart began manufacturing in March 2022. Dr. Jennifer Cope, the CDC scientist leading the investigation, confirmed that officials “couldn’t isolate it to specific lots from a certain time period.”
Independent laboratory tests revealed 36 samples from three different lots contained botulism-causing bacteria, forcing the company to acknowledge that contamination risks may have affected their entire product line.
Federal health officials have expanded an outbreak of infant botulism tied to recalled ByHeart baby formula to include all illnesses reported since the company began production in March 2022.
Read more: https://t.co/ryz33MhBUW pic.twitter.com/wHxlsjxsEB
— ABC News (@ABC) December 11, 2025
Pattern of Regulatory Failures Exposed
ByHeart’s contamination problems extend far beyond the current crisis, revealing a troubling pattern of regulatory violations. In 2022, the company recalled five batches after testing positive for cronobacter sakazakii, a dangerous pathogen.
The FDA issued a warning letter in 2023 detailing ongoing corrective action failures. Most damaging, FDA inspectors shut down the company’s Reading, Pennsylvania plant in 2023 after discovering mold, water leaks, and insect contamination—clear evidence of systematic manufacturing failures.
Parents Demand Corporate Accountability
Affected families are pursuing legal action against ByHeart, alleging the company’s negligence endangered their children’s lives. Andi Galindo, whose 5-week-old daughter was hospitalized with botulism in December 2023, expressed outrage over the expanded timeline.
“If there were issues with their manufacturing from the beginning, they really need to be held accountable,” she stated. The lawsuits seek compensation for medical bills, emotional distress, and other damages resulting from the company’s defective products.
Federal Response Highlights Regulatory Gaps
The outbreak represents the first confirmed case of infant botulism linked to powdered formula, exposing potential gaps in federal oversight of baby food manufacturing. While the FDA sent inspectors to ByHeart facilities in Iowa and Oregon, the agency has not released inspection results.
This incident underscores concerns about whether federal regulators adequately protect American families from corporate negligence. The Trump administration’s focus on accountability and regulatory reform becomes crucial as parents demand stronger protections for infant formula safety.
